Granulocyte colony-stimulating factor treatment provides neuroprotection in surgically induced brain injured mice

Acta Neurochir Suppl. 2011:111:265-9. doi: 10.1007/978-3-7091-0693-8_44.

Abstract

Surgically induced brain injury (SBI) is a common concern after a neurosurgical procedure. Current treatments aimed at reducing the postoperative sequela are limited. Granulocyte-colony stimulating factor (G-CSF), a hematopoietic growth factor involved in the inflammatory process, has been shown in various animal models to be neuroprotective. Consequently, in this study, we investigated the use of G-CSF as a treatment modality to reduce cell death and brain edema, while improving neurobehavioral deficits following an SBI in mice. Eleven-week-old C57 black mice (n=76) were randomly placed into four groups: sham (n=19), SBI (n=21), SBI with G-CSF pre-treatment (n=15) and SBI with G-CSF pre/post-treatment (n=21). Treated groups received a single dose of G-CSF intraperitoneally at 24, 12 and 1 h pre-surgery and/or 6 and 12 h post-surgery. Postoperative assessment occurred at 24 h and included neurobehavioral testing and measurement for both cell death and brain edema. Results indicated that pre-treatment with G-CSF reduced both cell death and brain edema, while post-treatment reduced neurobehavioral deficits. This study implies that the morphological changes in the brain are effected by pre-treatment; however, in order to activate and/or amplify targets involved in the recovery process, more dosing regimens may be needed.

Publication types

  • Research Support, N.I.H., Extramural

MeSH terms

  • Animals
  • Brain Edema / prevention & control
  • Brain Injuries / complications
  • Brain Injuries / etiology
  • Brain Injuries / prevention & control*
  • Cell Death / drug effects
  • Disease Models, Animal
  • Dose-Response Relationship, Drug
  • Drug Administration Schedule
  • Enzyme-Linked Immunosorbent Assay
  • Exploratory Behavior / drug effects
  • Functional Laterality / drug effects
  • Granulocyte Colony-Stimulating Factor / therapeutic use*
  • Mice
  • Movement / drug effects
  • Nervous System Diseases / etiology
  • Nervous System Diseases / prevention & control
  • Neuroprotective Agents / therapeutic use*
  • Neurosurgical Procedures / adverse effects*
  • Psychomotor Performance / drug effects
  • Time Factors
  • Treatment Outcome
  • Vibrissae / drug effects

Substances

  • Neuroprotective Agents
  • Granulocyte Colony-Stimulating Factor